Partnership in early drug development
January 23, 2013
Johnson & Johnson has posted an 8% increase in sales for the fourth quarter, helping by a strong showing at its pharmaceuticals division
Full story
July 18, 2012
Johnson & Johnson has kicked off the US reporting season by posting a 49.3% fall in earnings for the second quarter, hit by charges, and healthy sales of new products, notably the prostate cancer drug Zytiga
February 22, 2012
Johnson & Johnson has picked Alex Gorsky to take over from William Weldon as chief executive at the end of April